Be the first to review this item
Omaron (Piracetamum + Cinnarizinum, Piracetam + Cinnarizine) - combined medication with anti-hypoxic, neuroprotective and vasodilator effect.
Piracetam activates the metabolic processes in the brain by enhancing the energy and protein metabolism, accelerate the utilization of glucose into cells and increase their resistance to hypoxia, improves interneuronal transmission in the central nervous system, improves regional blood flow in the ischemic area.
Cinnarizine - selective blocker of slow calcium channels inhibits calcium ion entry into cells and reduces their content in the depot plasmolemma reduces the tonus of smooth muscle of the arterioles, reduces their response to biogenic vasoconstrictors (epinephrine, norepinephrine, dopamine, angiotensin, vasopressin). It has a vasodilating effect (particularly with regard to vessels of the brain, strengthening anti-hypoxic effect of piracetam), without significant effects on blood pressure. Exhibits mild antihistamine activity, reduces the excitability of the vestibular apparatus, lowers the tone of the sympathetic nervous system. Erythrocyte membrane elasticity increases, their ability to deform, reducing blood viscosity.
Precautions should be prescribed to patients with liver disease and / or kidney. In renal insufficiency, mild to moderate severity, especially in QC
In patients with impaired hepatic function should be monitored content of liver enzymes.
Precautions should be prescribed to patients with increased intraocular pressure, as well as in Parkinson's disease.
During treatment should avoid alcohol.
Effects on ability to drive vehicles and management mechanisms
During treatment, patients should be careful when driving and operating machinery.
In an application with Omaron may increase the sedative action of oppressive central nervous system activity and neuroprotective, antihypertensive drugs, ethanol.
Vasodilators increase the effect of the drug.
Omaron improves the tolerability of antipsychotic drugs and tricyclic antidepressants.
Adults appoint Table 1-2. 3 times / day for 1-3 months depending on the severity of the disease; Children - 1-2 tab. 1-2 times / day. Do not use the drug for more than 3 months.
Important notice- the outer box design may vary before prior notice!